In pancreatic ductal adenocarcinoma (PDAC), overexpression of OSBP2 was associated with short survival, enhanced tumor progression, and chemotherapy resistance to gemcitabine (GEM) and 5-fluorouracil (5-FU)34. Here, OSBP2 is linked to pancreatic ductal adenocarcinoma.